



## **German Court Issues Preliminary Injunction Against amedes Fetalis® Test for Infringement of Non-Invasive Prenatal Screening Patent**

SAN DIEGO & BURLINGTON, N.C.— October 24, 2016— Illumina, Inc. (NASDAQ: ILMN) and Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH), the world’s leading healthcare diagnostics company, today announced that on October 5, 2016, the Düsseldorf Regional Federal Court in Germany issued a preliminary injunction order against amedes MVZ Trägergesellschaft Göttingen mbH and a related company (collectively “amedes”). The order requires amedes to immediately stop performing the Fetalis® non-invasive prenatal screening test in Germany, which is based on technology from Ariosa Diagnostics, Inc.

The Application for the Grant of a Preliminary Injunction against amedes was filed by Sequenom, Inc., a wholly-owned subsidiary of LabCorp®, as patent owner of EP 0 994 963. The patent relates to the detection of cell-free fetal DNA for non-invasive prenatal screening. Illumina exclusively licenses the patent in the field of in vitro diagnostics.

Illumina and Sequenom have significant intellectual property rights in the area of non-invasive prenatal screening and will continue to enforce those rights when appropriate. This suit adds to prior patent infringement suits filed against others in Europe, Australia and the United States.

### **About Illumina**

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit [www.illumina.com](http://www.illumina.com) and follow @illumina.

## **About LabCorp®**

Laboratory Corporation of America® Holdings (NYSE:LH), an S&P 500 company, is the world's leading healthcare diagnostics company, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and develops technology-enabled solutions to change the way care is provided. With net revenue in excess of \$8.5 billion in 2015, LabCorp's 50,000 employees serve clients in 60 countries. To learn more about LabCorp, visit [www.labcorp.com](http://www.labcorp.com), and to learn more about Covance Drug Development, visit [www.covance.com](http://www.covance.com).

## **Contacts**

Illumina, Inc.

Investors:

Rebecca Chambers

858-255-5243

[ir@illumina.com](mailto:ir@illumina.com)

or

Media:

Tina Amirkiai

858-882-6822

[pr@illumina.com](mailto:pr@illumina.com)

or

David Robertson, Europe, Middle East and Africa

+44 1223 824909

[drobotson@illumina.com](mailto:drobotson@illumina.com)

or

Laboratory Corporation of America® Holdings

Investor Relations:

Paul Surdez, 336-436-5076

Vice President, Investor Relations

[Investor@labcorp.com](mailto:Investor@labcorp.com)

or

Media Relations:

Pattie Kushner, 336-436-8263

Vice President, Corporate Communications

[Media@labcorp.com](mailto:Media@labcorp.com)